间充质干细胞在腹膜透析中的研究进展  

Research advances of mesenchymal stem cells during peritoneal dialysis

作　　者：罗鑫满 邹循亮 Luo Xin-man;Zou Xun-liang(Department of Nephrology,Fifth Affiliated Zhuhai Hospital,Zunyi Medical University,Zhuhai 519000,China)

机构地区：[1]遵义医科大学第五附属(珠海)医院肾内科,珠海519000

出　　处：《临床肾脏病杂志》2023年第6期499-502,共4页Journal Of Clinical Nephrology

基　　金：国家自然科学基金(81860143);广东省医学科学技术研究基金(A2019436);贵州省卫生计生委科学技术基金(gzwjkj2018-1-014)。

摘　　要：腹膜透析(peritoneal dialysis,PD)是终末期肾病患者的主要治疗方式之一。长期PD容易出现腹膜炎症、上皮间充质转化(epithelial-mesenchymal transition,EMT)、新血管生成及纤维化,最终导致超滤衰竭和透析失败。随着干细胞临床治疗应用越来越成熟,近期相关研究表明间充质干细胞(mesenchymal stem cells,MSCs)在治疗PD相关性腹膜纤维化方面颇具前景。MSCs具有自我更新及多系分化能力,通过抑制免疫、炎症反应、调控EMT及纤维化通路延缓PD相关性腹膜纤维化的进展。本文就MSCs在PD中的作用机制、现存问题和前景进行综述。Peritoneal dialysis(PD)is one major treatment for patients with end-stage renal disease(ESRD).Long-term PD predisposes to peritoneal inflammation,epithelial-mesenchymal transition(EMT),angiogenesis,fibrosis and a failure of ultrafiltration and dialysis.Recent studies have demonstrated that mesenchymal stem cells(MSCs)are promising for treating PD-associated peritoneal fibrosis as clinical applications of stem cells become more sophisticated.Capable of self-renewal and multilineage differentiation,MSCs could arrest the progression of PD-related peritoneal fibrosis through blunting immune and inflammatory responses and modulating EMT and fibrosis pathways.This review summarized the underlying mechanisms,outstanding issues and future prospects of the role of MSCs during PD.

关 键 词：间充质干细胞 腹膜透析 腹膜纤维化 

分 类 号：R692.5[医药卫生—泌尿科学]